Sronyx

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sronyx

Quick Facts

Property Description
Active ingredient Levonorgestrel, Ethinyl Estradiol
Form Oral Tablet
Pharmacological class Combined Oral Contraceptive (COC)
Common use Reversible Contraception / Pregnancy Prevention
Origin Synthetic Hormonal Agent

What Type of Medicine is Sronyx?

Sronyx is a prescription medicine classified as a Combined Oral Contraceptive (COC), which is primarily used for reversible contraception and pregnancy prevention. This medication is administered via the oral route as a solid tablet, a recognized method for systemic hormonal agents. Combined oral contraceptives are a recognized strategy for family planning. Sronyx is formulated for efficacy in preventing pregnancy.

Composition: A Fixed-Dose Synthetic Combination

The active ingredients in Sronyx are the synthetic steroid hormones Levonorgestrel and Ethinyl Estradiol. Both Ethinyl Estradiol (a synthetic estrogen) and Levonorgestrel (a synthetic progestin) are laboratory-produced hormonal agents, establishing Sronyx as a synthetic hormonal agent. The product is defined as a combination product because it contains two distinct active substances, and it is structured as a monophasic regimen. This means that a fixed dose of both the synthetic estrogen and the synthetic progestin remains consistent across every active tablet in the cycle.

How this Combined Hormonal Agent Functions

Sronyx works through a primary mechanism of action: the suppression of ovulation. The combined synthetic hormones signal the body to prevent the release of an egg from the ovaries each month, which is the necessary step for conception. This fundamental contraceptive effect is supported by secondary protective measures, specifically the modification of the cervical mucus to inhibit sperm transport and alterations to the uterine lining that minimize the chance of implantation. These layered mechanisms are designed to provide efficacy for the medicine's stated general purpose for women seeking reversible contraception.

Regulatory References

  1. oral route (DailyMed Label for Sronyx)

What side effects are possible with Sronyx?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety characteristics of Sronyx (Levonorgestrel and Ethinyl Estradiol), based strictly on government regulatory documents. The information is presented at a high, non-instructional level.

Adverse Reaction Classification

Side effects are categorized by frequency as defined in official regulatory labeling:

  • Very Common (ge 1/10): Headache, breakthrough bleeding, and spotting.
  • Common (ge 1/100 to < 1/10): Nausea, abdominal pain, weight gain, mood changes, and breast tenderness.
  • Uncommon (ge 1/1,000 to < 1/100): Fluid retention, rash, and decreased libido.

Adverse reactions are formally grouped by the System Organ Class (SOC) affected, including Vascular Disorders, Gastrointestinal Disorders, Nervous System Disorders, and Reproductive System and Breast Disorders.

Serious Adverse Reactions and Safety Constraints

Official regulatory documents emphasize the risk of Serious Adverse Reactions, primarily involving the vascular system. Combined oral contraceptives are associated with an elevated risk of Venous Thromboembolism (VTE), which includes Deep Vein Thrombosis and Pulmonary Embolism, and Arterial Thromboembolism (ATE), such as stroke and myocardial infarction.

Time-Related Safety Patterns documented in labeling indicate that the risk of VTE is generally highest during the first year of use or when treatment is restarted after a break of four weeks or more. Nausea and vomiting are also commonly observed at the initiation of treatment.

Safety-Related Restrictions include an absolute contraindication for use in females over 35 who smoke, due to the substantial increase in serious cardiovascular risk, and in individuals with severe hepatic impairment, as noted in official prescribing information.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Sronyx (Levonorgestrel and Ethinyl Estradiol) classifies acute overdose as generally non-life-threatening. However, the ingestion of a large dose requires immediate regulatory-mandated action.

Documented Overdose Manifestations

Domain Manifestation as Stated in Official Labeling
Gastrointestinal Nausea and vomiting are documented clinical presentations.
Reproductive System Withdrawal bleeding may occur in females, including prepubertal female patients, following the ingestion of a large dose.

Required Emergency Actions

The official prescribing information mandates that individuals should seek immediate medical attention or contact emergency services upon suspected ingestion of a large dose. This action is necessary because, while severe outcomes are uncommon, the symptoms require evaluation and management. Treatment for Sronyx overdose is officially described as symptomatic and supportive in nature, as no specific antidote is known for the effects of the combination of Levonorgestrel and Ethinyl Estradiol.

Individuals experiencing documented manifestations or who suspect a large-dose ingestion must contact a poison control center immediately for guidance on supportive care.

Therapeutic Uses of Sronyx

What Sronyx Treats: Main Uses and Benefits

The combined oral contraceptive pill, which includes Sronyx, is commonly used for reliable pregnancy prevention and may be part of symptomatic management for several conditions related to the menstrual cycle. These medications are commonly used to help with painful, heavy, or irregular periods and are also applied in addressing acne. Indications include the management of severe menstrual pain (dysmenorrhea), excessive blood loss (HMB), irregular cycle timing, and hormonal acne.

Symptom Management and Patient Benefits

Sronyx is commonly used across conditions characterized by periods of heightened symptoms such as severe cramping and excessive bleeding. It helps address symptom clusters that create noticeable physiological strain, assisting in the management of discomfort associated with these recurrent episodes. By moderating these manifestations, the medication contributes to easing the overall symptom load and may assist with maintaining day-to-day comfort during symptomatic periods. This supports the patient's goal for a more predictable, regulated menstrual cycle and supports skin condition management.


Quick Fact: Management of Menstrual Discomfort

Symptom Domain General Benefit Provided
Dysmenorrhea (Painful Cramps) Helps ease the overall symptom burden.
HMB (Heavy Bleeding) Contributes to maintaining functional stability.
Acne (Hormonal) Supports skin condition management.

Regulatory References

  1. MedlinePlus Medical Encyclopedia overview on combination birth control pills

Eligibility and Restrictions for Use

The official regulatory guidance for the use of Sronyx (Levonorgestrel/Ethinyl Estradiol) strictly defines patient eligibility, primarily through a list of contraindications where use is absolutely prohibited. Sronyx is allowed for use by females of reproductive potential (those who have reached menarche).

However, the medicine is contraindicated in women over the age of 35 who smoke, and in any individual with a history of or current venous thromboembolism (VTE), arterial thromboembolic disease, or migraine headaches with focal neurological symptoms. Use is also prohibited in patients with hormone-sensitive malignancies (such as breast cancer) or with active severe liver disease and liver tumors. Eligibility is further restricted by physiological state:

  • Pregnancy: The medicine is contraindicated if pregnancy is known or suspected.
  • Lactation: Use is not recommended for nursing mothers, as it may affect breast milk production.
  • Age Limits: The medicine is not indicated for use before menarche or after menopause.

Furthermore, the medicine must be discontinued at least four weeks before and two weeks after major surgery or during prolonged immobilization due to the risk of VTE.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents classify drug interactions with Sronyx (Levonorgestrel/Ethinyl Estradiol) into high-risk prohibited combinations and those that modify hormone exposure.

Category
Contraindicated Combinations
Co-administration with specific Hepatitis C drug regimens, including combinations containing Ombitasvir, Paritaprevir, and Ritonavir (with or without Dasabuvir), is officially prohibited due to the risk of significant liver enzyme (ALT) elevations. The combination with oral Tranexamic Acid is also contraindicated due to pharmacodynamic synergism that increases the risk of thromboembolic events.
Medicines Reducing Hormone Exposure
Substances that induce metabolic enzymes, such as certain anticonvulsants (e.g., Phenytoin, Carbamazepine), the antibacterial Rifampicin, and the herbal product St. John’s Wort, can increase the clearance of Sronyx's hormones, officially documented as potentially decreasing contraceptive effectiveness.
Medicines Increasing Hormone Exposure
CYP3A4 inhibitors (e.g., Azole antifungals) and certain preparations of Grapefruit Juice can inhibit hormone metabolism, potentially increasing the plasma concentrations of Levonorgestrel and Ethinyl Estradiol.
Effect on Other Medicines
Sronyx is documented to affect the metabolism of co-administered drugs. For instance, it may decrease the plasma concentration of Lamotrigine while increasing the levels of drugs like Cyclosporin and Caffeine.
Absorption and Lifestyle Notes
Bile Acid Sequestrants (e.g., Colesevelam) interfere with absorption, requiring a mandatory timing separation in administration. Furthermore, the combination is officially contraindicated in females over 35 years of age who smoke due to the serious cardiovascular risk associated with tobacco use.

The regulatory interaction profile establishes mandatory constraints, including formal prohibitions and the documented risk of decreased contraceptive protection due to metabolic or absorption-based pharmacokinetic changes.

Mechanism of Action

Targeted Modulation of Specific Receptors

Sronyx functions as a modulator, interacting with defined biological targets within specific receptor or enzyme systems. This initial molecular action serves to either initiate or suppress distinct signaling events at the cellular level. This selective influence focuses the drug's activity on core regulatory mechanisms within the affected physiological systems.

Influencing Signal Transduction Cascades

Following its primary interaction, Sronyx operates within well-characterized molecular cascades, adjusting the dynamics of information flow mediated by key cellular messengers. This mechanism-driven interference is relevant in biological contexts where targeted pathway adjustment is required due to heightened or dysregulated pathway activation.

Supporting Regulation of Physiological Responses

By influencing these signaling pathways, Sronyx engages mechanisms that mediate the regulation of overactive or dysregulated processes. The resultant effect is a contribution to stabilizing physiological responses and supports a more regulated state within targeted central and/or peripheral pathways.

Dosage and Administration Information

How Sronyx is Used: Administration Guidelines

Sronyx, a Combined Oral Contraceptive (COC) containing Levonorgestrel and Ethinyl Estradiol, is administered orally in a fixed-dose, sequential cyclic regimen. Standard usage protocols focus on administration patterns, timing, and duration.

Standard Dosage and Schedule

The regimen is structured around a 28-day cycle consisting of 21 active hormonal tablets followed by 7 inert (non-hormonal) tablets. The typical dose is fixed across the active phase, such as 0.15 mg Levonorgestrel / 0.03 mg Ethinyl Estradiol per active tablet. One tablet must be taken once daily without interruption, for 28 consecutive days.

Key Administration Instructions

Instruction Entity Administration Instruction
Timing and Food Relation The tablet must be taken at the same time each day to maintain consistent hormone levels; it may be taken with or without food.
Initiation Protocols Treatment is initiated using either the Day 1 Start or the Sunday Start method.
Missed Dose Protocol Specific instructions detail immediate actions for one or more missed tablets, which may include taking multiple tablets in one day and the temporary need for backup non-hormonal contraception.

Use Constraints

Administration must be stopped at least 4 weeks before and for 2 weeks after major surgery involving prolonged immobilization. Furthermore, administration is not indicated for postmenopausal women and should be delayed until 4 weeks postpartum for non-breastfeeding women. The continuous use of the fixed-dose cyclic pattern is intended for the duration of the requirement for reversible contraception.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Sronyx

Evidence for Use in Pregnancy Prevention (Contraception)

Research examined the use of Sronyx, which contains levonorgestrel and ethinyl estradiol, primarily through Randomized Controlled Trials (RCTs) and Open-label Efficacy Studies in healthy women of reproductive age. The core outcomes monitored included the occurrence of pregnancy and the hormonal suppression of ovulation. Study findings described the rates of pregnancy occurrence documented in populations that reported high adherence to the daily regimen.

However, the rates observed in controlled clinical trials often represent situations of perfect adherence, and research indicates that the rates documented in real-world settings may differ. Limited information is available from dedicated, long-term RCTs that track contraceptive performance in highly specific patient subgroups with certain underlying medical conditions.


Research on Symptom Management: Menstrual Pain (Dysmenorrhea)

The combination was evaluated in research exploring outcomes related to Primary Dysmenorrhea, a condition characterized by periods of heightened symptoms. The evidence base for this relies on RCTs and systematic reviews focusing on combined oral contraceptives (COCs) as a class. Research examined outcomes related to physical discomfort, specifically by measuring standardized pain severity scores and monitoring the reported frequency of rescue pain medication use. Comparative evidence directly against every alternative therapy for this specific low-dose formulation is limited, and there is limited information for long-term outcomes beyond the intermediate study durations (three to six treatment cycles).


Research on Symptom Management: Hormonal Acne

The combination was studied in research exploring outcomes related to Hormonal Acne in women with mild to moderate acne vulgaris. Research included Randomized Controlled Trials (RCTs) that often compared the pill against a placebo or other hormonal combinations. The primary outcomes measured included changes in acne lesion counts and severity grading. Trials reported the patterns observed in lesion counts over time, with effects on skin requiring multiple treatment cycles to be measured. Comparative evidence remains limited for a direct, head-to-head evaluation against every other hormonal therapy for acne management.


Evidence Gaps and Research Uncertainty

While initial trials describe group patterns for the primary indication, research does not determine whether an individual will respond similarly to the medication. The research provides context but not individual predictions. Rates reported in controlled settings are also considered distinct from real-world performance, where research suggests adherence can vary.

Frequently Asked Questions (FAQ)

Common questions about Sronyx (FAQ)

Q: How is Sronyx different from other birth control pills?

A: Sronyx is officially described as a combined oral contraceptive that contains a fixed, monophasic dose of the synthetic hormones levonorgestrel and ethinyl estradiol. This composition is consistent throughout the active tablets in the cycle. This fixed-dose combination and specific hormone pair distinguishes it from other oral contraceptives that may use different hormone types or fluctuating (phasic) dosing schedules.

Q: Is it common to have spotting or breakthrough bleeding while taking Sronyx?

A: Official product information notes that breakthrough bleeding and spotting are very common adverse reactions, meaning they occur in many users. This is particularly noted as being more frequent during the first few months of use. It is a known pattern that often decreases as the body adjusts to the medication.

Q: How long does it take for Sronyx to start working for contraception?

A: If use is initiated on the first day of the menstrual cycle, regulatory documents describe the onset of contraceptive effect as immediate. If use begins at other times in the cycle, official protocols describe the need for backup non-hormonal contraception for the first 7 consecutive days while the hormones establish their full effect.

Q: How long does the withdrawal bleed last while using Sronyx?

A: The bleeding typically starts during the week when the 7 non-hormonal (inert) tablets are taken. Regulatory information indicates the bleeding usually begins within a few days of stopping the active tablets and often does not finish until the next pack is started.

Q: Can Sronyx be used while breastfeeding?

A: Official product information states that combined oral contraceptives are not generally recommended for nursing mothers. Studies indicate that the hormones may decrease the quantity and quality of breast milk produced. Official product information notes this factor when considering contraceptive options.

Q: Can Sronyx be used by someone with a history of depression?

A: Official product labeling notes that mood changes are a common adverse reaction associated with the use of this type of medication. If a female experiences depression during use, the official guidance advises that a healthcare provider should assess whether the medication should be discontinued.

Q: What are the signs of a serious side effect from Sronyx?

A: Official warnings emphasize the potential risk of serious vascular events, such as blood clots (thromboembolism). Symptoms associated with these serious events include sudden, severe chest pain, shortness of breath, sudden numbness or weakness on one side of the body, sudden severe headache, or swelling and pain in a leg or arm.

Q: Is it necessary to take Sronyx at the exact same time every day?

A: Regulatory documents state that taking the tablet at the same time each day is required to maintain consistent hormone levels. Guidance for a single missed hormonal pill often defines the acceptable late window as up to 24 to 48 hours late, depending on the specific product's instructions, before contraceptive protection is officially considered reduced.

Q: Does Sronyx cause weight gain?

A: Weight gain is listed in official documents as a common adverse reaction noted in clinical trials. This describes an association observed in a significant number of participants. Regulatory summaries generally report this finding as an association noted in trials, and the specific physiological mechanism is not definitively established.

Q: Does Sronyx help with acne?

A: Official information may note that the specific combination of hormones in Sronyx has been examined in clinical trials for its effect on managing mild to moderate acne vulgaris. While its primary purpose is contraception, the data suggests it may be used to address symptoms related to hormonal acne.

Q: Can Sronyx affect mood or cause mood swings?

A: According to the official product information, mood changes are listed as a common adverse reaction. This describes the fact that changes in emotional state were reported by users in clinical trials.

Q: What happens if you accidentally miss a Sronyx pill?

A: Missed dose instructions detail that protection may be reduced, especially if a pill is missed early in the cycle or if multiple hormonal pills are missed. The protocols generally require the use of backup non-hormonal contraception until a full 7 consecutive days of active pills have been taken correctly.

Q: Can Sronyx be used for purposes other than preventing pregnancy?

A: The primary approved indication is pregnancy prevention. However, the drug is also studied and sometimes officially indicated for the management of other conditions, such as primary dysmenorrhea (menstrual pain) and the treatment of moderate hormonal acne.

Q: Does Sronyx have a risk for liver problems?

A: Official labeling lists severe liver disease and liver tumors as contraindications for use. Additionally, the label warns that taking Sronyx with certain Hepatitis C medications may cause significant liver enzyme (ALT) elevations, and users are advised to stop the medication if jaundice develops.

Q: Is the evidence for Sronyx based on large clinical trials?

A: Official efficacy for combined oral contraceptives is established based on large clinical studies. These trials typically involve thousands of women monitored over multiple treatment cycles to gather data on contraceptive effectiveness.

Q: Why do official documents describe the drug's purpose as X and Y?

A: Official documents describe all the approved therapeutic indications for the drug. This includes the primary purpose of preventing pregnancy, as well as any other uses, such as the treatment of moderate acne or dysmenorrhea, for which the product has received regulatory clearance.

Q: Is Sronyx available as a generic version?

A: Sronyx is the brand name of the medicine. Regulatory records confirm that products containing the same active ingredients, Levonorgestrel and Ethinyl Estradiol, are available as authorized generics or other generic formulations.

Q: Does Sronyx affect fertility long-term?

A: The drug's mechanism of action is described as reversible, primarily suppressing ovulation only while the medicine is being taken. Official documentation does not indicate that use causes long-term impairment or permanent sterility after the medication is discontinued.

Q: Are certain types of pain relievers known to interact with Sronyx?

A: The combination is specifically contraindicated with oral Tranexamic Acid. While official labeling does not typically note interactions with common over-the-counter pain relievers like Ibuprofen or Acetaminophen, interactions with certain prescription medications are documented.

Q: What is the likelihood of getting pregnant while using Sronyx correctly?

A: Data from controlled clinical studies indicate that when combination oral contraceptives are used exactly as directed ('perfect use'), the effectiveness rate is documented as being over 99.7%. This figure reflects the failure rate observed in trial populations under controlled conditions.

Q: Does Sronyx affect cholesterol levels?

A: Official product labeling notes that combined oral contraceptives may affect lipid (cholesterol) metabolism. The label advises that an alternative contraceptive method be considered for women with uncontrolled dyslipidemias, and monitoring may be required.

Q: Does Sronyx change how the body processes sugar?

A: Regulatory documents state that combined oral contraceptives may decrease glucose tolerance in some users. For women with prediabetes or diabetes, the label advises monitoring glucose levels while they are using this medication.

Q: What is the active ingredient's half-life in Sronyx?

A: Pharmacokinetic data from official documents shows the elimination half-life for the active ingredient Levonorgestrel is approximately 36 hours at steady state. The half-life for Ethinyl Estradiol is approximately 18 hours at steady state.

Q: Does Sronyx affect the body's natural hormones long-term?

A: Sronyx functions by providing synthetic hormones to suppress the body's natural cycle hormones and prevent ovulation. This mechanism is fully reversible upon discontinuation. Official documents do not indicate that the medication causes long-term or permanent changes to the body’s endogenous hormone regulation.

Q: Is Sronyx connected to changes in hair loss or hair growth?

A: Official adverse reaction listings for the combination product note that changes in hair growth patterns, such as hirsutism (increased hair growth) or alopecia (hair loss), have been reported in post-marketing or clinical trial data.

How should Sronyx be stored and disposed of?

How to Store and Dispose of Sronyx

Sronyx (Levonorgestrel and Ethinyl Estradiol Tablets USP) must be stored at Controlled Room Temperature (CRT), defined as 20° to 25° C (68° to 77° F). This medicine must be kept out of the reach of children.

Storage Requirements

The tablets require protection from light and moisture and should remain in their original container. Storing the product outside of the controlled temperature range may compromise the stability of the active hormonal agents.

Disposal Requirements

Do not dispose of unused, unwanted, or expired Sronyx by flushing it down the toilet or pouring it into a drain. To ensure proper pharmaceutical waste handling, utilize an official drug take-back program when available. If a take-back program is not accessible, mix the tablets with an unappealing substance, seal them in a container, and discard them in the household trash, following local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sronyx found in:

A-Z Index: